Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

Medicine and Dentistry

• Patient 100%
• Drug 100%
• Multiple Sclerosis 100%
• Therapeutic Procedure 50%
• Fluoxetine 50%
• Amiloride 50%
• Riluzole 50%
• Analysis 25%
• Brain 25%
• Magnetic Resonance Imaging 16%
• Adverse Event 16%
• Medicine 16%
• Expanded Disability Status Scale 16%
• Disease 8%
• Health Care Cost 8%
• Infection 8%
• Incidence 8%
• Obesity 8%
• Age 8%
• Clinical Research 8%
• Lung Cancer 8%
• Ischemic Heart Disease 8%
• Disability 8%
• Intention-to-Treat Analysis 8%
• Nurse 8%
• Sudden Death 8%
• Program Evaluation 8%
• Neurodegeneration 8%
• DNA Template 8%
• Masking 8%
• Coronary Artery Thrombosis 8%
• Neuroprotection 8%
• Clinical Neuroscience 8%